The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Open accessAbstract
The role of KRAS, when activated through canonical mutations, has been well established in cancer1. Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas2–4. KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS–GTP levels. Here we demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacologically, can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings. These data demonstrate the relevance of copy-number amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition. Amplification of wild-type KRAS in a subset of gastroesophageal tumors drives intrinsic resistance to MAPK inhibition that can be overcome by combined targeting of MEK and SHP2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, inhibition of SHP2 was recently shown to overcome RTK-driven adaptive feedback mechanisms to MEK inhibition, and enhance the efficacy of MEK inhibitor induced growth suppression in vitro and in vivo in RAS-driven cancers (27,41–44).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous experiences with trametinib, a clinical MEK inhibitor have taught us that targeted inhibition of Ras downstream effectors, including MEK would inevitably trigger the relief of ERK-mediated feedback inhibition of RTK signaling, which results in adaptive Ras reactivation that heavily depends on SHP2.86”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the inhibition of SHP2, which connects RTKs to the RAS signaling pathway and is particularly vulnerable in cancer cells with genetic alteration in KRAS, has attracted considerable attention (12, 56–59).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“In these regards, SHP2 was purposed as a combinatorial target in overcoming the resistance to MEK inhibition and presumably for drugs targeting K-RasG12C.32,86,87”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [86]
In the citing paper
“These findings echo prior studies showing that inhibition of RTK-driven feedback reactivation with SHP2 inhibitors can improve the response to MEK inhibitors [107,108,109].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [109]
In the citing paper
“Recent studies in KRAS-mutant lung cancer (54, 55) and pancreatic adenocarcinoma (55), KRAS-amplified gastric carcinoma (56), and multiple other cancer models expressing mutant or wild-type KRAS (57, 58) revealed that the anti-tumor effect of MEK inhibitor treatment could be dramatically potentiated by concurrent SHP2 inhibition.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · cited 1×
“SHP099, a potent and selective allosteric inhibitor to the catalytic site of SHP2, was recently developed 20,21 .”
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2960 · Cited by 850
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture
Miyoshi, H., & Stappenbeck, T. S. (2013) · Nature Protocols · doi:10.1038/nprot.2013.153 · Cited by 739
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 736
Self-citationRas history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Cited by
Sorted by citations
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Self-citationVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265
Self-citationTargeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S. E., Moore, K. L., Joshi, S. S., Landron, S., Johnson, J., Kiedrowski, L. A., Nagy, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1704 · Cited by 232
Self-citationLee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S., Odegaard, J. I., Harrington, E. A., Lee, J.-Y., Lee, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0442 · Cited by 230
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Yuan, X., Bu, H., Zhou, J., Yang, C., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 221
Self-citationAhmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.013 · Cited by 214
The KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 229
Self-citationNew clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 217
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Zhao, M., Guo, W., Wu, Y., Yang, C., Zhong, L., Deng, G., Zhu, Y., Liu, W., Gu, Y., Lu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.009 · Cited by 190
Targeting SHP2 as a promising strategy for cancer immunotherapy
Liu, Q., Qu, J., Zhao, M., Xu, Q., & Sun, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104595 · Cited by 178
Mapping the genomic diaspora of gastric cancer
Yeoh, K. G., & Tan, P. B. O. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00412-7 · Cited by 175
Zhang, H., Schaefer, A., Wang, Y., Hodge, R. G., Blake, D. R., Diehl, J. N., Papageorge, A. G., Stachler, M. D., Liao, J., Zhou, J. R., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0811 · Cited by 170
Self-citationTyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
Song, Z., Wang, M., Yang, G., Chen, X.-P., Xu, Z., Sun, Y., & Xiong, X. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.07.010 · Cited by 139
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
KRasG12C inhibitors in clinical trials: a short historical perspective
Goebel, L., Müller, M. P., Goody, R. S., & Rauh, D. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00096e · Cited by 135
Kerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Therapeutic targeting of RAS: New hope for drugging the “undruggable”
Khan, I., Rhett, J. M., & O’Bryan, J. P. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118570 · Cited by 111
Vainonen, J. P., Momeny, M., & Westermarck, J. K. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe2967 · Cited by 106
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Tang, K. H., Li, S., Khodadadi-Jamayran, A., Jen, J., Han, H., Guidry, K., Chen, T., Hao, Y., Fedele, C., Zebala, J. A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0369 · Cited by 105
Self-citationTyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08115-8 · Cited by 103
Ozkan‐Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz‐Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 104
Self-citationDissection of gastric cancer heterogeneity for precision oncology
Ho, S. W. T., & Tan, P. B. O. (2019) · Cancer Science · doi:10.1111/cas.14191 · Cited by 103
Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
Xu, Z., Guo, C., Ye, Q., Shi, Y., Sun, Y., Zhang, J., Huang, J., Huang, Y., Zeng, C., Zhang, X. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26697-8 · Cited by 100
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Pan, Y., Han, H., Hu, H., Wang, H., Song, Y., Yuan, H., Tong, X., Patel, A. S., Misirlioğlu, S., Tang, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.015 · Cited by 97
Self-citationImproving outcomes in patients with oesophageal cancer
Shah, M. A., Altorki, N. K., Patel, P., Harrison, S. W., Bass, A. J., & Abrams, J. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00757-y · Cited by 103
Self-citationLu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
Wang-Bishop, L., Chen, Z., Gomaa, A. R., Lockhart, A. C., Salaria, S. N., Wang, J., Lewis, K. B., Ecsedy, J., Washington, K. M., Beauchamp, R. D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.10.030 · Cited by 92
Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
Bagdanoff, J. T., Chen, Z., Acker, M., Chen, Y., Chan, H., Dore, M., Firestone, B., Fodor, M., García‐Fortanet, J., Hentemann, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01725 · Cited by 92
Leung, C. O. N., Tong, M., Chung, K. P. S., Zhou, L., Che, N., Tang, K. H., Ding, J., Lau, E. Y.-T., Ng, I. O., Ma, S., et al. (2019) · Hepatology · doi:10.1002/hep.30989 · Cited by 88
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 98
KRAS G12C Mutations in NSCLC: From Target to Resistance
Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 85
SOS GEFs in health and disease
Baltanás, F. C., Zarich, N., Rojas-Cabañeros, J. M., & Santos, E. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188445 · Cited by 100
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 80
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
Kim, J. W., Márquez, C. P., Kostyrko, K., Koehne, A. L., Marini, K. D., Simpson, D. R., Lee, A. G., Leung, S. G., Sayles, L. C., Shrager, J. B., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0612-2 · Cited by 79
Therapeutics Targeting Mutant KRAS
Thein, K. Z., Biter, A. B., & Hong, D. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 76
Catenacci, D. V. T., Moya, S. M., Lomnicki, S., Chase, L. M., Peterson, B. F., Reizine, N. M., Alpert, L., Setia, N., Xiao, S., Hart, J. A. L., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1408 · Cited by 72
Self-citationGenomics and Targeted Therapies in Gastroesophageal Adenocarcinoma
Nagaraja, A. K., Kikuchi, O., & Bass, A. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0487 · Cited by 70
Self-citationEarly stage gastric adenocarcinoma: clinical and molecular landscapes
Hirata, Y., Noorani, A., Song, S., Wang, L., & Ajani, J. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00767-w · Cited by 76
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 69
Self-citationThe role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects
Yuan, W., Shi, Y., Dai, S., Deng, M., Zhu, K., Xu, Y., Chen, Z., Zhou, X., Zhang, T., & Song, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05998-8 · Cited by 68
Bala, P., Rennhack, J. P., Aitymbayev, D., Morris, C. X., Moyer, S. M., Duronio, G. N., Doan, K. T., Li, Z., Liang, X., Hornick, J. L., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf0927 · Cited by 70
Gao, J., Wu, Z., Zhao, M., Zhang, R., Li, M., Sun, D., Cheng, H., Qi, X., Shen, Y., Xu, Q., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.006 · Cited by 64
Self-citationProtein Tyrosine Phosphatases: Mechanisms in Cancer
Sivaganesh, V., Sivaganesh, V., Scanlon, C., Iskander, A., Maher, S., Le, T. H., & Peethambaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312865 · Cited by 64
Wang, K., Liu, Y., Li, J., Xiao, C., Wang, Y., Gu, W., Li, Y., Xia, Y., Yan, T., Yang, M.-H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33761-4 · Cited by 64
Rocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 71
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Ren, Q., Zhang, P., Zhang, X., Feng, Y., Li, L., Lin, H., & Yu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199040 · Cited by 63
Valencia-Sama, I., Ladumor, Y., Kee, L., Adderley, T., Christopher, G., Robinson, C. M., Kano, Y., Ohh, M., & Irwin, M. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3822 · Cited by 62
Strategies to overcome drug resistance using SHP2 inhibitors
Liu, M., Gao, S., Elhassan, R. M., Hou, X., & Fang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.037 · Cited by 58
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Niogret, C., Birchmeier, W., & Guarda, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02468 · Cited by 58
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0170 · Cited by 53
Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance
Zandi, Z., Kashani, B., Alishahi, Z., Pourbagheri‐Sigaroodi, A., Esmaeili, F., Ghaffari, S. H., Bashash, D., & Momeny, M. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03874-2 · Cited by 49
Imamura, Y., Watanabe, M., Oki, E., Morita, M., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12406 · Cited by 52
Self-citationLong-read sequencing for non-small-cell lung cancer genomesPreprint
Sakamoto, Y., Xu, L., Seki, M., Yokoyama, T., Kasahara, M., Kashima, Y., Ohashi, A., Shimada, Y., Motoi, N., Tsuchihara, K., et al. (2020) · Genome Research · doi:10.1101/gr.261941.120 · Cited by 45
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma
Atabay, E. K., Mecca, C., Wang, Q., Ambrogio, C., Mota, I. A., Prokoph, N., Mura, G., Martinengo, C., Patrucco, E., Leonardi, G. C., et al. (2021) · Blood · doi:10.1182/blood.2020008136 · Cited by 52
Chen, W. S., Liang, Y., Zong, M., Liu, J. J., Kaneko, K., Hanley, K. L., Zhang, K., & Feng, G.-S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109974 · Cited by 50
Self-citationGebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26526-y · Cited by 49
Avery, T. Y., Köhler, N., Zeiser, R., Brummer, T., & Ruess, D. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931774 · Cited by 51
Structural impact of GTP binding on downstream KRAS signaling
Menyhárd, D. K., Pálfy, G., Orgován, Z., Vida, I., Keserű, G. M., & Perczel, A. (2020) · Chemical Science · doi:10.1039/d0sc03441j · Cited by 50
A KRAS-responsive long non-coding RNA controls microRNA processing
Shi, L., Magee, P., Fassan, M., Sahoo, S., Leong, H. S., Lee, D. C. H., Sellers, R., Brullé, L., Cairo, S., Monteverde, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22337-3 · Cited by 50
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Linehan, A., O’Reilly, M., McDermott, R., & O'Kane, G. M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369136 · Cited by 57
Thinking Differently about Cancer Treatment Regimens
Settleman, J., Neto, J. M. F., & Bernards, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1187 · Cited by 52
Liu, M., Gao, S., Tao, L., Qiu, X., Yang, X., Fang, H., & Hou, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00866 · Cited by 45
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
Hill, K. S., Roberts, E. R., Wang, X., Marin, E. M., Park, T. D., Son, S., Ren, Y., Fang, B., Yoder, S., Kim, S., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0777 · Cited by 47
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Chen, Y., Liu, Q.-P., Xie, H., & Ding, J. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01194-4 · Cited by 45
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Cremer, A., Ellegast, J. M., Alexe, G., Frank, E. S., Ross, L. S., Chu, S. H., Pikman, Y., Robichaud, A. L., Goodale, A. B., Häupl, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0209 · Cited by 42
Frank, K. J., Mulero-Sánchez, A., Berninger, A., Ruiz-Cañas, L., Bosma, A., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100815 · Cited by 40
Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs
Angata, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02885 · Cited by 42
An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase
Anselmi, M., & Hub, J. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-75409-7 · Cited by 39
Shipping out MEK inhibitor resistance with SHP2 inhibitors
Torres-Ayuso, P., & Brognard, J. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0915 · Cited by 37
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodríguez, F. J., Gross, J. M., Allen, A. N., Wan, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02305-x · Cited by 38
Wang, S. C., Yeu, Y., Hammer, S. T. G., Xiao, S., Zhu, M., Hong, C., Clemenceau, J. R. V., Yoon, L. Y., Nassour, I., Shen, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2918 · Cited by 38
Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
Zheng, Z.-Y., Chu, M.-Y., Lin, W., Zheng, Y.-Q., Xu, X., Chen, Y., Liao, L., Wu, Z., Wang, S., Li, E., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04941-3 · Cited by 39
Self-citationEssakly, A., Loeser, H., Kraemer, M., Alakus, H., Chon, S., Zander, T., Buettner, R., Hillmer, A. M., Bruns, C. J., Schroeder, W., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.10.013 · Cited by 40
A New View of Activating Mutations in Cancer
Nussinov, R., Tsai, C., & Jang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2125 · Cited by 36
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33
Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2–mediated signaling
Sang, Y., Hou, Y., Cheng, R., Zheng, L., Alvarez, A. A., Hu, B., Cheng, S., Zhang, W., Li, Y., & Feng, H. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz107 · Cited by 36
Dampening oncogenic RAS signaling
Bivona, T. G. (2019) · Science · doi:10.1126/science.aav6703 · Cited by 33
Tsujino, T., Sugito, N., Taniguchi, K., Honda, R. P., Komura, K., Yoshikawa, Y., Takai, T., Minami, K., Kuranaga, Y., Shinohara, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14035 · Cited by 33
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
Sethi, N. S., Kikuchi, O., McFarland, J. M., Zhang, Y., Chung, M., Kafker, N., Islam, M., Lampson, B. L., Chakraborty, A. A., Kaelin, W. G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128439 · Cited by 35
Self-citationTargeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 34
Self-citationTyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?
Chen, X., Keller, S. J., Hafner, P., Alrawashdeh, A. Y., Avery, T. Y., Norona, J., Zhou, J., & Ruess, D. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340726 · Cited by 38
Self-citationGarcía‐Navas, R., Liceras-Boillos, P., Gómez, C., Baltanás, F. C., Calzada, N., Nuevo‐Tapioles, C., Cuezva, J. M., & Santos, E. (2021) · Oncogene · doi:10.1038/s41388-021-01886-3 · Cited by 29
SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology
Baltanás, F. C., García‐Navas, R., & Santos, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126613 · Cited by 31
Yang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31
Self-citation
Metadata
- Authors
- Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., Zou, C., Dulak, A., Henderson, L., Xu, P., O’Day, E., Rendak, R., Liao, W.-L., Cecchi, F., Hembrough, T., Schwartz, S., Szeto, C., Rustgi, A. K., Wong, K.-K., Diehl, J. A., Jensen, K., Graziano, F., Ruzzo, A., Fereshetian, S., Mertins, P., Carr, S. A., Beroukhim, R., Nakamura, K., Oki, E., Watanabe, M., Baba, H., Imamura, Y., Catenacci, D., & Bass, A. J.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of Chicago Medical Center (US)
- Broad Institute (US)
- OncoPlex Diagnostics (United States) (US)
- Abramson Cancer Center (US)
- Harvard University (US)
- Medical University of South Carolina (US)
- University of Illinois Urbana-Champaign (US)
- University of Urbino (IT)
- Kumamoto University (JP)
- Kyushu University (JP)
- The Cancer Institute Hospital (JP)
- Corresponding author
- Catenacci, Daniel
- Bass, Adam J.
- ORCID
- Zhou, Jin
- Wu, Zhong
- Li, Tianxia
- Schumacher, Steven E.
- Puschhof, Jens
- McFarland, James
- Zou, Charles
- Dulak, Austin
- Henderson, Les
- Xu, Peng
- O’Day, Emily
- Hembrough, Todd
- Schwartz, Sarit
- Szeto, Christopher
- Rustgi, Anil K.
- Wong, Kwok-Kin
- Diehl, J. Alan
- Jensen, Karin
- Graziano, Francesco
- Ruzzo, Annamaria
- Fereshetian, Shaunt
- Mertins, Philipp
- Carr, Steven A.
- Beroukhim, Rameen
- Nakamura, Kenichi
- Oki, Eiji
- Watanabe, Masayuki
- Baba, Hideo
- Imamura, Yu
- Catenacci, Daniel
- Bass, Adam J.
- Venue
- Nature Medicine
- Published
- 2018-05-28
- Volume
- 24
- Issue
- 7
- Pages
- 968-977
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6039276
- OpenAlex
- W2804957989
- Semantic Scholar
- 6af671acbd44534590b63fcb147e769f8ce02fc2
- Cited by
- 266
- References
- 48
- Citations by year
- 2026: 22 · 2025: 20 · 2024: 41 · 2023: 24 · 2022: 32 · 2021: 46 · 2020: 36 · 2019: 36 · 2018: 9
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-08-09)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion, cc-by-nc-nd)
- Funders
- Japan Society for the Promotion of Science (16H06259)
- National Cancer Institute (P50CA127003, P01CA098101, K23CA178203, P30CA014599)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- gastroesophageal cancer, gastric cancer, esophageal adenocarcinoma, MEK inhibition, SHP2 inhibition, SOS1, SOS2, MAPK signaling, MAPK inhibitor resistance, combination therapy, guanine nucleotide exchange factor, protein tyrosine phosphatase
- MeSH terms
- Animals, Disease Models, Animal, Esophageal Neoplasms, Gene Amplification, Humans, Piperidines, Pyridones, Pyrimidines, Pyrimidinones, Stomach Neoplasms, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
